CA3005889A1 - Formulations de cannabinoide a liberation continue - Google Patents

Formulations de cannabinoide a liberation continue Download PDF

Info

Publication number
CA3005889A1
CA3005889A1 CA3005889A CA3005889A CA3005889A1 CA 3005889 A1 CA3005889 A1 CA 3005889A1 CA 3005889 A CA3005889 A CA 3005889A CA 3005889 A CA3005889 A CA 3005889A CA 3005889 A1 CA3005889 A1 CA 3005889A1
Authority
CA
Canada
Prior art keywords
cannabinoid
composition according
mixture
per tablet
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3005889A
Other languages
English (en)
Inventor
Jeff Scott Renwick
Robert Lefler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canntab Therapeutics Ltd
Original Assignee
Canntab Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/923,066 external-priority patent/US20180263953A1/en
Application filed by Canntab Therapeutics Ltd filed Critical Canntab Therapeutics Ltd
Publication of CA3005889A1 publication Critical patent/CA3005889A1/fr
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3005889A 2017-08-30 2018-05-23 Formulations de cannabinoide a liberation continue Pending CA3005889A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762551924P 2017-08-30 2017-08-30
US62/551,924 2017-08-30
US15/923,066 US20180263953A1 (en) 2016-09-27 2018-03-16 Sustained Release Cannabinoid Formulations
US15/923,066 2018-03-16

Publications (1)

Publication Number Publication Date
CA3005889A1 true CA3005889A1 (fr) 2019-02-28

Family

ID=65519436

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3005889A Pending CA3005889A1 (fr) 2017-08-30 2018-05-23 Formulations de cannabinoide a liberation continue

Country Status (1)

Country Link
CA (1) CA3005889A1 (fr)

Similar Documents

Publication Publication Date Title
CA3036585A1 (fr) Formulations de cannabinoides a liberation prolongee
AU2018233582B2 (en) Modified release multi-layer tablet cannabinoid formulations
US20180263953A1 (en) Sustained Release Cannabinoid Formulations
AU2022202259B2 (en) Novel cannabinoid formulations
US11590230B2 (en) Compositions of therapeutic substances, methods and uses thereof
BR112021001326A2 (pt) formulações de liberação prolongada de canabinoides
CA3141987A1 (fr) Formulations de cannabinoides
WO2019082171A1 (fr) Compositions de cannabinoïdes orales ayant une biodisponibilité améliorée
US20230172844A1 (en) Cannabidiol orally disintegrating tablets
JPS63162627A (ja) 徐放性医薬製剤
CN107847437B (zh) 用于治疗疼痛的塞来昔布口服组合物
JP2021535935A (ja) ナノ乳化による製剤化カンナビス油粉末、その製造方法、及びその使用
Ahmad et al. Silymarin: an insight to its formulation and analytical prospects
US20180250262A1 (en) Sustained release cannabinoid formulations
US20180263954A1 (en) Sustained Release Cannabinoid Formulations
KR20070112252A (ko) 신규한 연질 젤라틴 캡슐
Zhang et al. Strategic developments in the drug delivery of natural product dihydromyricetin: applications, prospects, and challenges
CA3005885A1 (fr) Pastilles de cannabinoide a liberation continue
CA3005889A1 (fr) Formulations de cannabinoide a liberation continue
WO2023015378A1 (fr) Stabilisation de résine de cannabis et formulations orales solides de cannabinoïdes
JP4575717B2 (ja) アンピロキシカム含有医薬組成物とその安定化方法及びその製造方法
Martínez et al. Trends in oral flavonoid drug delivery systems based on current pharmaceutical strategies. A systematic patent review (2011-2023)
Gunjal et al. Enhancing the oral bioavailability of fisetin: polysaccharide-based self nano-emulsifying spheroids for colon-targeted delivery
Ezhilarasi Development and Characterization of Fexofenadine Hydrochloride Oil Entrapped Floating Alginate Beads to Enhance Oral Bioavailability
JP2024500552A (ja) 水溶性カンナビノイド製剤及びその製造方法